Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland

NCT05363488 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2023-04-03

No results posted yet for this study

Summary

This study will describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia (CML) used in a real world clinical practice setting.

Conditions

  • Myeloid Leukemia

Interventions

DRUG

Bosutinib

Patients receiving bosutinib treatment

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-08
Primary Completion
2021-10-08
Completion
2021-10-08

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05363488 on ClinicalTrials.gov